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Abstract 
Objectives: Prostate cancer (PC) is the most common cancer in Western countries. Recent advances in the 
treatment of metastatic castration resistant prostate cancer (mCRPC) have caused significant pressure on health 
care budgets. We aimed to exemplify this dilemma presenting an example, radium-223 (Xofigo®), and review 
the literature.  
Methods: A 74-year-old man diagnosed with mCRPC was referred to our department in October 2014 for 
radium-223 therapy. We faced the following dilemma: is radium-223 standard therapy? Is it cost-effective? 
Medline was searched employing the following search criteria: “radium-223”, “alpharadin”, “Xofigo” and 
“prostate”. Exclusion and inclusion criteria were applied. Guidelines and cost-effectiveness analyses were 
focused. We also searched the websites of ASCO, ESMO and ISPOR. The web was searched, using Yahoo and 
Google search engines, for Health Technology Assessments (HTAs).  
Results: 181 publications were identified in the Medline database. Only four studies included the word “cost”, 
three “economics” and none “budget” in heading or abstract. None of the publications were thorough of cost 
analysis (cost-effectiveness, cost-utility, cost-minimizing or cost-of-illness analysis). Six HTAs and eight 
national guidelines were identified. The cost per quality adjusted life years was indicated €80.000-94,000. HTAs 
concluded reimbursement being not recommendable or no ultimate statement could be made. One pointed 
towards a limited use with caution.  
Conclusion: Guidelines were based on data from randomized clinical trials (RCTs). Health economics was not 
considered when guidelines were made. Most HTAs concluded this therapy not cost-effective or there was 
insufficient data for final conclusions. Licensing and reimbursement processes should be run simultaneously.  
Keywords: Radium-223, prostate cancer, economics, guidelines 
1. Introduction 
Prostate cancer (PC) is the most common cancer in Western countries, and rates are second only to lung cancer 
as the cause of cancer related mortality in men (Basch et al., 2014; Mohler et al., 2013; Cancer registry of 
Norway, 2014; Von Moos, Sternberg, Body, & Bokemeyer, 2013; Liu et al., 2014). Most patients are diagnosed 
at an early stage and managed by primary curative treatment or active surveillance (Cancer registry of Norway, 
2014). Unfortunately, around 4% of patients are initially diagnosed with metastatic disease (Seal, Asche, Puto, & 
Allen, 2013). About 30% of men diagnosed with early prostate cancer develop advanced disease (Hansen, Seal, 
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Wen, Valderrama, & Sullican, 2013). The 5-year expected survival of this subgroup (diagnosed with advanced 
disease or has developed metastatic disease) is poor despite treatment with androgen deprivation therapy (ADT). 
Medical castration or surgical castration has been the most common upfront therapy. Patients who relapse after 
primary ADT usually have a progression free survival of 18-24 months and develop metastatic castration 
resistant prostate cancer (mCRPC) (Seal et al., 2013). Despite the use of chemotherapy in mCRPC, the survival 
advantages have been very limited. Docetaxel based regimens have prolonged median overall survival by about 
three months (Petrylak et al., 2004). 
Recently, radium-223, an alpha()-emitting radiopharmaceutical has been documented beneficial in mCRPC 
(Sartor, Heinrich, & Helle, 2012; Hoskin et al., 2014; Parker et al., 2013). Advances have especially been made 
in the treatment of bone metastasis. Bone is the site of more than 90% of the metastases in this group of patients 
(Parker et al., 2013). In the main trial, the average patient received 6-monthly doses of radium-223 and the 
median overall survival (OS) was 14.9 months in the radium-223 group and 11.3 months in the placebo group, 
respectively. Radium-223 has been approved in several countries for the treatment of mCRPC. Guidelines for the 
use have been based on results from randomized clinical trials (RCTs) (Basch et al., 2014, Cassinello, Climent, 
González del Alba, Mellado, & Virizuela, 2014, Arranz Arija, Cassinello Espinosa, Climent Durán, & Rivero 
Herrero, 2012). But, in many countries the therapy has not been approved for reimbursement (Mohler et al., 
2013; Roach, 2014). Guidelines for the use have been based on results from randomized clinical trials (RCTs) 
(Basch et al., 2014; Cassinello, Climent, González del Alba, Mellado, & Virizuela, 2014; Arranz Arija, 
Cassinello Espinosa, Climent Durán, & Rivero Herrero, 2012).   
Costs and availability considerations should influence on treatment decisions (Basch et al., 2014). Limited health 
care resources have alternative use, and would therefore provide health gains in other patient-groups. Hence, 
there is an increasing concern to compare the expected health outcomes from a new intervention with its costs. 
Whereas health care administrators frequently have to deal with early approval of new drugs, simultaneously 
reimbursement and/or budget coverage of raised costs have often been delayed. In this study, we aim to illustrate 
this dilemma employing radium-223 as an example. 
2. Methods 
2.1 Case History 
A 74-year-old man was diagnosed with locally advanced prostate cancer and lymph node metastases (T3 N1) in 
2003. In 2011, skeletal metastases were documented and chemotherapy (docetaxel) initiated. Due to disease 
progression, enzalutamide was introduced in 2013. In October 2014, progression of skeletal metastases was 
documented and the patient was referred to the Section of nuclear medicine, Department of Radiology, 
University hospital of North Norway (UNN) for initiation of radium-223 therapy. According to national 
recommendations (Norwegian Directorate of Health, 2014), a preoperative CT-scan was performed and disclosed 
no visceral metastases. The referral raised two major questions: Is radium-223 considered standard therapy? Is it 
cost-effective? 
2.2 Literature Search 
To answer these questions, we searched the web pages of the Norwegian Medicines Agency (NMA) 
(www.slv.no), Norwegian Labour and Welfare Administration (www.nav.no), Ministry of Health and Care 
Services (www.hod.dep.no) and the Norwegian Directorate of Health’s (www.helsedirektoratet.no) in December 
2014 employing the following search criteria: “radium-223”, “alpharadin” and “Xofigo®”. Furthermore, we 
conducted a systematic literature search in December 2014 on all documents and articles published in the 
English language using the MEDLINE® database (www.ncbi.nlm.nih.gov/pubmed). The search terms were 
“prostate”, “Xofigo®”, “radium-223” and “alpharadin”. We also searched the Internet using the Yahoo 
(www.yahoo.com) and Google (www.google.com) search engines. The search criteria were “HTA”, “Xofigo®”, 
“223-radium”, “alpharadin” and “prostate”. Additional material was identified searching congress abstracts, 
including American Society of Clinical Oncology (ASCO) (www.asco.org), European Society for Medical 
Oncology (ESMO) (www.esmo.org) and International Society for Pharmacoeconomics and Outcome Research 
(ISPOR) (www.ispor.org). An overview is shown in Table 1.   
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Table 1. The search strategy and criteria employed when searching the Medline database and web pages of 
several cancer associations. (ASCO = American Society of Clinical Oncology, ESMO = European Society for 
Medical Oncology, ISPOR = International Society for Pharmacoeconomics and Outcome Research) 
Source Search criteria Hits Selected 
Medline (PubMed) Prostate cancer, Xofigo®, radium-223 and alpharadin 181 14 
ASCO Radium-223 with prostate 94 2 
ESMO Radium-223 with prostate 134 0 
ISPOR Radium-223 7 6 
 
2.3 Data Extraction and Evidence Rating 
One reviewer used the titles and abstracts identified in the initial literature search to identify potentially relevant 
publications. The full text versions of relevant publications were retrieved and evaluated. Study characteristics 
were extracted and summarized for the included publications. The eligible articles were assigned a level of 
evidence as follows: High: Evidence from well designed randomized controlled trials. Moderate: Evidence from 
well-designed nonrandomized controlled trials. Low: Evidence from well-designed observational studies with 
controls, including retrospective and case-control studies. Very low: Observational studies without controls, 
including cohort studies without controls and case series. 
2.4 Statistics and Authorization 
The data accessed were from open sources without any identifiable individual patient data. Our case history was 
presented in an anonymous version and the patient was not implemented in any research protocol or given any 
unproven therapy. Consequently, no approval from the Regional Committees for Medical and Health Research 
Ethics (REK) was necessary. The data from the literature was summarized employing the Microsoft Office Excel 
2007. Costs were converted into Euros (€) according to the exchange rates of the Central Bank of Norway 
(www.norges-bank.no) the 30th of December 2014. 
3. Results 
3.1 Guidelines 
Overall, 181 publications were identified through the MEDLINE® database. Four studies included the word 
“cost” in its heading or abstract (Roach, 2014; Vogelzang, 2014; Mongiat-Artus et al., 2013; Dellis & Papatsoris, 
2014). Furthermore, no studies included the word “budget” and three studies the word “economics” (Roach, 
2014; Vogelzang, 2014; Mongiat-Artus et al., 2013). None of these publications included an economic evaluation 
(cost-effectiveness, cost-utility, cost-minimizing or cost-benefit analysis). Consequently, they were concluded of 
very low level of evidence. Ten publications included the word “guideline(s)” (Basch et al., 2014; Mohler et al., 
2013; Cassinello, 2014; Arranz et al., 2012; Cookson, Lowrance, Murad, & Kibel, 2014; Ryan, Saylor, Everly, & 
Sartor, 2014; Heidenreich et al., 2014; El-Amm & Aragon-Ching, 2013; Badawi, 2012; Bourgeois, Kraus, 
Maaloof, & Sartor, 2011). They represented guidelines from American Urological Association (AUA) (Cookson 
et al., 2014), Sociedad Española de Oncología Médica (SEOM) (Cassinello et al., 2014), American Society of 
Clinical Oncology (ASCO), Cancer Care Ontario (CCO) (Basch et al., 2014), National.  
Comprehensive Cancer Network (NCCN) (Mohler et al., 2013), European Association of Urology (EAU) 
(Heidenreich et al., 2014) and the European Society of Medical Oncology (ESMO) (Horwich, Parker, de Reijke, 
& Kataja, 2013). Searching the Internet, we also detected the guidelines of the Norwegian Directorate of Health 
(2014) and the Swedish National Board for Health and Welfare (2014). They were based on well-designed RCTs 
and concluded of high level of evidence. An overview is given in Table 2. 
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Table 2. Summary of various guidelines´ recommendations for the use of radium-223 in metastatic prostate 
cancer. (CRPC = castration-resistant prostate cancer, QALY = quality adjusted life years) 
Reference Institution Conclusions 
Horwich et al., 
2013. 
European Society of 
Medical Oncology 
(ESMO). 
Recommend bone targeted therapy with one of the beta particle emitting 
radio-nucleotides should be considered for patients with painful bone 
metastases. Ra-223 may become a new treatment option for symptomatic 
patients. 
Casinello et al., 
2014 
Sociedad Española de 
Oncología Médica 
(SEOM). 
Recommend patients with only bone disease and nodes less than 2 cm to be 
considered for radium-223. 
Basch et al., 2014. American Society of 
Clinical Oncology 
(ASCO) and Cancer 
Care Ontario (CCO). 
Recommend radium-223 offered to men with bone metastases and state that 
cost-effectiveness assessment is not included in their guideline. 






A favourable toxicity profile and extension of survival renders radium-223 an 
attractive first-line or second-line option for patients with symptomatic bone 
metastases and no known visceral disease. Radium-223 given in combination 
with chemotherapy outside clinical trials is not recommended.  
Heidenreich et al., 
2014. 
European Association 
of Urology (EAU). 






Directorate of Health. 
The use of isotopes may be considered for patients with symptomatic bone 
metastases when external radiotherapy has limited effect and docetaxel has 
been considered/used. Ra-223 has documented effect, but is not licensed and 
has not undergone national cost-effectiveness analysis.  
Swedish National 
Board for Health 
and Welfare, 2014 
Swedish National 
Board for Health and 
Welfare. 
Radium-223 may be indicated in patients with mCRPC with skeletal 
metastases and following chemotherapy (when appropriate). High evidence 
of effect, but cost per QALY is very high. The figures are uncertain.  
 
The SEOM recommended patients with bone disease and nodes less than 2 cm considered for radium-223 
therapy (Cassinello et al., 2014; Arranz et al., 2012). The ASCO and CCO guidelines recommend radium-223 
offered to men with bone metastases, but stated that cost-effectiveness assessment was not included in their 
guideline (Basch et al., 2014). The cost per infusion was USD $12,455 (€10,212), and they added that some of 
the suggested therapies have been found not cost-effective by various authorities worldwide. Similarly, the 
NCCN and EAU guidelines did not consider cost Mohler et al., 2013). The EAU concluded radium-223 
available for second-line treatment of CRPC following docetaxel (Heidenreich et al., 2014). ESMO recommend 
one of the beta particle emitting radionucleotides used (strontium-89, samarium-153) (Horwich et al., 2013). 
They added radium-223 may become a new treatment option. The Norwegian Directorate of Health (2014) 
mentioned radium-223 an available therapy, but stated that it had not been licensed for use in Norway or 
undergone national cost-effectiveness analysis. Consequently, the answer on our first question was “no”.  
3.2 HTA Analysis 
An overview of the Health Technology Assessments (HTAs) with regard to radium-223 is shown in Table 3. The 
National Centre for Pharmacoeconomics (NCPE) (2014) in Ireland calculated the incremental cost-effectiveness 
ratio (ICER) to be €79,948. The Ludwig Boltzmann Institute for HTA (2014) in Austria would not give any 
concluding recommendations, because radium-223 had not been examined in combination with systemic 
therapies, including enzalutamide, abiraterone acetate or docetaxel. Furthermore, they concluded risk of 
secondary malignancies, contamination from body fluids for medical staff and family members as well as the 
optimal dose of radium-223 had to be examined in post-marketing observations. The National Institute for 
Health and Care Excellence (NICE) (2014) noted that the manufacturer's base case ICER for radium-223 
compared with best supportive care was £55,500 (€70,800) per QALY gained. Adjustments to the model slightly 
increased the ICER to £57,400 (€73,200). Furthermore, the committee considered that addressing its concerns 
around the time horizon, health state utilities and costs would be likely to further increase the ICER. The 
appropriate comparison had not been presented. Consequently, it was not possible to determine whether 
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radium-223 could be considered a cost-effective use of National Health Services´ (NHS´) resources. Based on 
the comparison with best supportive care (BSC), the NICE-committee concluded radium-223 could not be 
considered a cost-effective use of NHS resources in England and Wales. In Sweden, the National Board for 
Health and Welfare (2014) did a health economic analysis as a supplement to the national Swedish guidelines. 
They concluded radium-223 offered an incremental gain of 0.20 QALYs compared to BSC. The cost per QALY 
was SEK 905,000 (€94,000). A sensitivity analysis revealed a range between SEK 492,000–2,203,000 
(€51,000-229,000). It was concluded that the cost per QALY was very high. 
Based on these reports, the answer to our second question was that radium-223 has not been documented 
cost-effective. 
 
Table 3. Summary of Health Technology Assessments (HTAs) of radium-223 (Xofigo®) used in 
castration-resistant prostate cancer. (ICER = incremental cost-effectiveness ratio, QALY = quality adjusted life 
years, ALSYMPCA = pivotal phase III trial of radium-223) 
Reference Institution Conclusions 
NCPE, 2014. 
National Centre for 
Pharmaco-economics 
(NCPE), Ireland. 
Following the assessment of the company submission, the NCPE 
considers that the cost-effectiveness of radium-223 has not been 
demonstrated. Reimbursement is not recommended. ICER €79,948. 
Ludwig Boltzmann 




Institute for Health 
Technology Assessment.  
No ultimate statement can be made because radium-223 was not 
examined in combination with a valid comparator. Furthermore, the 
risk of secondary malignancies, contamination from body fluids for 
medical staff and family members as well as the optimal dose of 
radium-223 need to be examined. Cost for radium-223 was 
$69,000-$82,800 (€52,600-67,900) in a six-month course of treatment. 
NICE, 2014. 
National Institute for 
Health and Care 
Excellence  
Base case ICER for radium-223 compared with best supportive care 
(BSC) was £55,500 (€70,800) per QALY. Concerns around the time 
horizon, utilities and costs would be likely to increase the ICER 
further. It was not possible to determine whether radium-223 could be 
considered a cost-effective use of NHS resources, because the 
appropriate comparison with docetaxel and abiraterone acetate had not 
been presented. Based on the comparison with BSC, radium-223 could 
not be considered a cost-effective use of NHS resources. 
IQWIG, 2013. 
German Institute for 
Quality and Efficiency in 
Health Care (IQWiG). 
Radium-223 in prostate cancer: Major added benefit for certain 
patients. In comparison with best supportive care (BSC): Patients 
survive longer and get bone symptoms later/no evaluable data in 
comparison with docetaxel. Depending on the patients’ age (</> 65 
yrs) and the concomitant treatment (with/without bisphosphonates), 
there is an indication of major and an indication of minor added 
benefit of radium-223 compared with BSC. 
Aberdeen 
HTA-group, 2013. 
Aberdeen HTA group. 
National Institute of Health 
Research (NIHR) 
The evidence is weaker to support the use of radium-223 for first line 
use as the 1st line patient population in ALSYMPCA is highly 
selective and radium-223 has not been compared against all valid 
comparators. Abiraterone acetate should be evaluated as a comparator. 
It is difficult to conclude whether the submission contains an unbiased 
estimate of the cost effectiveness of radium-223 dichloride. The 
exclusion of patients with visceral metastatic disease could be 
problematic for generalizing results to the wider treatment population. 
Results are particularly sensitive to the time horizon. The analysis of 
the EQ-5D quality of life data is limited.  
Swedish National 
Board for Health 
and Welfare, 2014. 
Swedish National Board 
for Health and Welfare. 
They conclude radium-223 offers a gain of 0.20 QALY compared to 
BSC. The cost/QALY was indicated SEK 905,000,- (€94,000). A 
sensitivity analysis indicated a range between SEK 492,000–2,203,000 
(€51,000-229,000).   
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3.3 Other Health Economic Analysis 
ISPOR´s website (www.ispor.no) provide six abstracts (five selected) (Seal et al., 2013; Hansen et al., 2013; Seal 
et al., 2012; Valderrama et al., 2014; Hao et al., 2013) and one publication (Biran et al., 2013) on any type of 
health economics with regard to radium-223. Seal and colleagues (2013), reported radium-223 increased life 
expectancy by 0.325 years in the intention to treat population (ITT), and it was projected to lead to 44% 
reduction in the cost of treatment of skeletal reported events (SREs). Hansen et al. (2013) calculated the budget 
implications of radium-223 in CRPC in the United States in a catchment area of 1 million lives. Seal and 
colleagues concluded the most common patient reported outcome (PRO) was pain (2012). Valderrama and 
co-workers (31) estimated the economic impact of radium-223 in the treatment of mCRPC to increase per 
member per month (PMPM) cost by $0.02 (€0.016). Hao et al. (2013) revealed the EORTC QLQ-C30 and 
FACT-P the most common quality of life (QoL) instruments used among patients with mCRPC. Seal and 
coworkers (2012) summarized the use (18%) of patient-reported outcomes (PRO) and tolerability measures in 
the studies reviewed.  
From the ASCO meetings, we disclosed two studies focusing on radium-223 and cost/savings. Cislo et al. (2014) 
reported radium-223 compared with placebo, resulted in a 23% reduction in incidence of hospitalizations per 
year and about 6.5 fewer hospitalization days per patient per year. Nilson et al. (2014) documented significantly 
increased odds of improved pain relief versus placebo.  
4. Discussion 
In this review, we have documented several studies reporting data on the use of radium-223 in the treatment of 
mCRPC. The few studies reporting any figures on the cost-effectiveness of this therapy were generally of low 
quality. Most guidelines did not include any economic considerations when giving their state of the art. When 
cost was mentioned, the guidelines gently touched the item by mentioning there are costs. Consequently, there 
were limited support and aid for health care administrators facing the dilemma to use or not to use radium-223 in 
their hospital. However, HTAs were supportive in this setting. 
Many new cancer drugs may improve median overall survival by some few months, but at an excessively high 
cost. Value-based insurance design and pricing schemes use the basic premise that an intervention's cost should 
be linked to the health gains it provides. This could potentially bring the cost of new medications closer to 
thresholds that would be considered cost-effective. Medications that are not considered value-for-money would 
consequently not be reimbursed. Western countries that have implemented a policy of universal coverage have 
struggled with rising health-care costs. New national agencies have been established to provide up-dated 
evidence (health technology assessments (HTA) for health care decision makers (NCPE, 2014; Ludwig 
Boltzmann Institute for Health Technology Assessment, 2014; NICE, 2014; IQWIG, 2013; MSAC, 2012; 
Aberdeen HTA group, 2013). In the past two decades, Ireland, Scotland, England, Wales, Germany, Austria, 
Sweden, Norway and others have conducted economic evaluations of new health interventions. These data have 
become an integral part of coverage decisions in national health-care and other-payer systems. The establishing 
of the Health Technology Assessment International (HTAI) (www.htai.org) is an example of this cooperation.  
In this study, we observed the speed of marketing and inclusion in guidelines of radium-223 was much faster 
than the reimbursement and health care budget process in Norway. The latter two make it possible for hospital 
owners and administrators to finance the new accepted therapies or stop them at an early stage (when this is 
concluded). In Norway, the case of radium-223 was sent to the NMA the 26th of September 2013 for analysis and 
the process for a fast track HTA was initiated in May 2014. In late February 2015, the decision to finance this 
therapy was made. The cost per life year gained was estimated between NOK 568,000-836,000 (€62,800 – 
92,500), but may vary from 400,000 to 1,200,000 (€44,200 – 132,700) due to uncertainties.  
Our case and review illustrated the need of an early “scanning” for upcoming new indications, drugs, methods 
and devices that may enter the market in the near future. Such a tool may be supported by an improved 
communication between health care administrators and clinicians, especially at university hospitals. Clinicians 
and researchers are frequently informed at an early setting through networks, international conferences and/or by 
taking part in phase I and II studies of promising new drugs. Such collaboration should be in the interest of all 
stakeholders; clinicians, researchers and administrators. This could speed up the process by simply securing an 
early warning. Consequently, patients may get access to new cost-effective therapies in an earlier setting. 
Collaboration between various groups was illustrated in our survey by the joint guideline by the ASCO and CCO 
(Basch et al., 2014). Similar co-operations between institutions making HTAs should be encouraged. Efficacy 
could simply be improved by the “reuse” of HTAs done in comparable countries. Alternatively, the workload 
could be allocated between collaborative institutions.  
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A delayed decision-making process concerning reimbursement increases the pressure on heads of departments 
and clinics as well as hospital and health care administrators waiting for final conclusion. This pressure may end 
up in different treatment cultures within the region/country and malpractices that may be difficult to overcome.  
The current state of drug approval in prostate cancer is ever changing and will bring future changes in the 
treatment paradigm. We therefore strongly suggest a coordinated process between approval, guidelines and 
reimbursement. The need for guidelines to provide optimal opportunity to patients to achieve effective treatment 
at the most appropriate time has been also been suggested by others (El-Amm et al., 2013). 
Availability has been an issue with regard to radium-223 (Incollingo, 2014). Due to manufacturing problems, the 
drug was temporarily suspended by its maker, Bayer HealthCare Pharmaceuticals. This caused a shortage of the 
product on the market, affecting patients and their relatives waiting for therapy. This illustrates that availability 
should also be of concern when guidelines and approvals are made.  
The HTAs revealed in our study documented the utmost importance that drug developers choose the appropriate 
comparator arm, when designing and performing clinical trials. Best supportive care may not be the appropriate 
arm, as illustrated by NICE (NICE, 2014). A new study (BAY 88-8223/15396) has now been initiated 
(radium-223 in combination with abiraterone acetate and prednisone/prednisolone) testing the drug in an earlier 
setting (asymptomatic or mildly symptomatic mCRPC). Furthermore, a standard health related QoL or pain 
instrument being consistently used across prostate cancer trials could be beneficial (Hao et al., 2013). Patient 
reported outcomes (PROs) should be incorporated in studies of new therapies for mCRPC (Seal et al., 2012). To 
enable comparisons of health outcomes across patient groups, we recommend the use of generic preference 
based outcome measures. 
5. Conclusion  
Guidelines were based on data from randomized clinical trials (RCTs). Health economics was not considered 
when guidelines were made. Most HTAs concluded this therapy not cost-effective or there was insufficient data 
for final conclusions. Licensing and reimbursement processes should be run simultaneously.  
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